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ABSTRAK
Gastroenteropati diabetik merupakan hal yang sering terjadi pada pasien diabetes melitus lama, terutama 
pada pasien yang dengan kontrol glikemi yang buruk maupun yang telah memiliki komplikasi lain, termasuk 
semua bentuk komplikasi diabetes pada saluran gastrointestintal, dimana menyebabkan berbagai keluhan 
seperti heartburn, nyeri perut, mual, muntah, bahkan sampai konstipasi, diare, dan inkontinensia fekal. Hal yang 
mendasari komplikasi ini berbeda-beda pada setiap organ maupun keluhan, seperti neuropati sistem saraf otonom 
yang, hilangnya Sel Interstitial Cajal sebagai pacemaker jaringan otot gaster sehingga menimbulkan dismotilitas, 
gangguan transportasi cairan dan fungsi motorik, serta hiperglikemia yang menyebabkan stres oksidatif, dan 
juga faktor lain seperti insulin-growth factor I yang mengakibatkan atrofi otot polos. Gastroenteropati diabetik 
secara jelas merupakan salah satu penyebab morbiditas pada pasien diabetes melitus. Diagnosis dari komplikasi 
gastroenteropati diabetik sangat perlu dicermati dan penting untuk menyingkirkan kemungkinan-kemungkinan 
lainnya. Manajemen dari komplikasi juga perlu diperhatikan dengan teliti karena selain menyelesaikan keluhan 
juga perlu menjaga kontrol glikemi yang baik. Dengan semakin meningkatnya jumlah pasien diabetes melitus 
dan prevalensi komplikasi gastroenteropati pada pasien diabetik masih belum tercatat jelas, disebabkan 
perhatian dan pengetahuan yang kurang oleh tenaga medis dalam mengenali bentuk komplikasi gastroenteropati; 
penting untuk dapat mengenali dan menangani secara dini pada pasien gastroenteropati diabetik agar dapat 
meningkatkan kualitas hidup dan penanganan diabetes yang baik.
Kata kunci: diabetes melitus, gastroenteropati, komplikasi, gastroparesis
ABSTRACT
Diabetic gastroenteropathy is a common complication in prolonged diabetic patients, particularly patients with 
poor glycemic control or other complications, including all form of diabetic complication on the gastrointestinal 
tract, which prompts various symptoms of heartburn, abdominal pain, nausea, vomiting, even constipation, 
diarrhea, and fecal incontinence. The underlying pathophysiology of this complication manifestations are 
different on each organ or symptom, but may include autonomic nervous system neuropathy, loss of Interstitial 
Cell of Cajal as gastric muscle pacemaker leading to dysmotility, impair of liquid transportation and motoric 
function, as well as hyperglycemia causing oxidative stress, and other factors like Insulin-Growth Factor I 
inducing smooth muscle atrophy. Diabetic gastroenteropathy is one of major morbidity on diabetes mellitus 
patients. Patients with this complication need to be well diagnosed and ruled out other diagnosis possibilities. 
Management of the complication includes resolving main symptoms and maintaining good glycemic control. 
With growing number of diabetes mellitus patients and the prevalence of diabetic gastroenteropathy complication 
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not being well recorded, caused by lack of attention and knowledge of healthcare provider in identifying the 
complication; it is important to be able to identify and to give early treatment to diabetic gastroenteropathy 
patients, to increase quality of life and maintain glycemic control of the patient.
Keywords: diabetes mellitus, gastroenteropathy, complication, gastroparesis.
INTRODUCTION
Diabetic gastroenteropathy is one of the most 
common complications in prolonged diabetic 
patients, particularly in patients either with poor 
glycemic control or with other complications 
concurrently. Diabetic gastroenteropathy as 
a complication of diabetes mellitus includes 
all form of diabetic complication on the 
gastrointestinal tract, which causes various 
symptoms involving heartburn, abdominal pain, 
nausea, vomiting, even constipation, diarrhea, 
and fecal incontinence. These symptoms 
significantly impair patients’ quality of life, 
as well as increasing patients’ morbidity from 
dehydration, electrolyte imbalance, and poor 
glycemic control.1-3
While diabetes mellitus global prevalence 
is increasing from 424.9 million patients in 
2017 to the estimated 628.9 million by 2045 
because of urbanization, lifestyle, and the 
tendency of obesity,4 the prevalence of diabetic 
gastroenteropathy is still not well recorded.1 
This could be due to lack of attention and 
knowledge of healthcare provider in identifying 
gastroenteropathy as a diabetic complication. 
Therefore, it is important to be able to identify 
and to early treat diabetic gastroenteropathy 
patients, to increase the quality of life and 
diabetic control of the patient.
In this literature, there will be explanations 
about complication manifestation, approach, 
and management in treating gastrointestinal 
complications in diabetic patients which divided 
by organ.
EPIDEMIOLOGY
The data of gastroenteropathy complication 
in diabetic patients is not readily available for 
the time being, but there was some research 
in the third level referral center which showed 
deviation from data collected in the lower level 
of health center. This is shown by the discordance 
of diabetic gastroenteropathy prevalence in the 
diabetes clinic of third level referral center as 
high as 76%-83%,5 whereas in community level 
or lower, mentioned symptoms only recorded as 
5-12%.3 On each symptom, esophagus prevalence 
was recorded as high as 63% on dysmotility and 
41% on reflux.6,7 Gastroparesis is one of the most 
complained symptoms, but the data in each 
research varied from 5 to 18 percents.8,9 On the 
intestinal symptoms, the majority of 60% was 
diagnosed with constipation followed by 20% 
of diarrhea complaint from diabetic patients. 
Differences in prevalence recorded probably due 
to lack of attention to recognize the signs and 
symptoms of gastroenteropathy, which brings 
us to the importance of knowing and treating the 
diabetic gastroenteropathy better.10
PATHOPHYSIOLOGY
The underlying pathophysiology on every 
diabetic gastroenteropathy manifestations is 
different on each organ or symptom. However, 
from every existing factor, autonomic neuropathy 
is the one most important aspect of the symptoms. 
Neuropathy on gastrointestinal tract can affect all 
organs as shown on Figure 1. Gastrointestinal 
neuropathy can affect vagal nerve, sympathetic 
and parasympathetic nervous system, or 
innervations of anal sphincter.5,11 Neuropathy 
on the autonomic nervous system is commonly 
found simultaneously progressing in chronic 
diabetes due to prolonged hyperglycemia.12
One of the neuropathies that have been 
discovered is the neuropathy of parasympathetic 
autonomic nervous system, vagal nerve with 
Wallerian degeneration, decrease of density 
and diameter of unmyelinated axons, thickening 
of Schwann’s Cell basal lamina, and decrease 
of collagen fibrils thickness, also abnormal 
endoneurial capillaries are found on diabetic 
patients.13,14 Autonomic neuropathy also affects 
the Interstitial Cell of Cajal (ICC) that has 
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been confirmed by researches on animal and 
human.15 ICC is the pacemaker of gastric 
muscle tissue, from which slow wave will start 
and then distributed in all directions with equal 
velocity.16 On diabetic patients, significant loss 
of ICC has been proved by gastric wall biopsies 
will promote an electrical dysrhythmia which 
later induces dysmotility symptoms such as 
dysphagia, gastroparesis, or constipation.17
Neuropathy also occurs on the sympathetic 
autonomic nervous system causing the 
impairment of liquid transportation and motoric 
function that lead to rapid bowel transit. This 
impairment of sympathetic nervous system 
not only manifests on bowel transit but also 
on α2-adrenergic, which controls internal anal 
sphincter tone, that will promote symptoms like 
fecal incontinence or nocturnal incontinence. 
Both sympathetic and parasympathetic nerve 
neuropathy may partially explain paradoxical 
symptoms such as diarrhea and constipation.18,19
Hyperglycemia is another underlying factor 
of the impaired gastrointestinal tract on diabetic 
patients. Hyperglycemia will cause oxidative 
stress from the imbalance of pro-oxidative 
and anti-oxidative factors. This imbalance will 
inhibit the neurite growth on the nerve that 
causes neurite degeneration (decrease of caliber, 
beading, and growth cone retraction) and also 
neuron apoptosis.13 Additionally, there are also 
factors like insulin-growth factor I, inducing 
an atrophic change of smooth muscle structure 
leading to decreased gastrointestinal functions.20
SYMPTOMS MANIFESTATION
Manifestation on Esophagus
Symptoms of esophagus impairments in 
diabetic patients are dysphagia, heartburn, 
even odynophagia. Dysphagia and heartburn 
are the manifestations from esophagus motoric 
function disorder in peristaltic movement or 
lower esophagus sphincter tone. This will lead 
to dilation of esophagus, gastric reflux, and 
even stalling of esophagus emptying.21 While 
odynophagia is commonly caused by candida 
esophagitis.13 Diabetic patients are often under 
an immunocompromised condition, so that 
opportunistic infection may emerge, including 
candida infection on esophagus.22
Disorder of esophagus motoric function 
is prompted by neuropathy complication of 
myenteric plexus, which regulates the activity 
of smooth muscle fibers in esophagus and lower 
esophageal sphincter. Then, this neuropathy 
affect remodeling of muscle structure in diabetic 
patients, which leads to esophageal motility 
disorder such as abnormal peristaltic movement, 
spontaneous contraction, and decreased lower 
esophageal sphincter tone.23
Heartburn is associated with gastroesophageal 
reflux in the diabetic patient, as high as 41%. 
Patients with neuropathy are more likely to be 
found with erosive esophagitis than the ones 
without neuropathy. Despite the high prevalence 
of erosive esophagitis and dysmotility, only a few 
give rise to symptoms, while a lot of others go 
asymptomatic. Therefore, gastroscopy is needed 
to confirm a diagnosis.24
Latterly complaint of odynophagia in diabetic 
patients should be thought as candida esophagitis. 
This diagnosis can be more confirmed if there are 
other findings like a plaque or typical stomatitis 
of oral candidiasis. However, to be noted that 
Figure 1. Innervation of gastrointestinal tract.13
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candida esophagitis can be found without oral 
candidiasis.13 Another possibility of odynophagia 
cause is other esophagitis such as viral, bacterial, 
or parasitic, in few cases. Further examination 
such as endoscopy is needed to ensure the 
causative diagonsis.25
Management
Further examinations are needed for 
esophageal manifestation including endoscopy 
to diagnose erosive esophagitis or candida 
esophagitis and the examination of reflux and 
dysmotility such as pH-meter and manometry.10,13 
With endoscopy, not only diagnosis, but also 
biopsy can be done to confirm and to brush the 
cream-like plaque.25 pH-meter is used to check 
the reflux whether it is acid, weak acid, or non-
acid. From manometry, or nowadays used is 
multichannel impedance manometry, we can find 
the pressure change during relaxation or during a 
bolus passes through the esophagus. By means of 
both pH-meter and manometry, we can evaluate 
the motility of esophagus.26
The first and the foremost in the therapeutic 
management of esophageal manifestation in 
diabetic patients is good glycemic control. By 
maintaining good glycemic control, complaints 
such as heartburn and dysphagia can be improved. 
For reflux disease, prokinetics and proton pump 
inhibitors can be applied.27 Candida esophagitis 
is managed by administering antifungal agent 
such as azole groups, if the complaint does not 
get better after consumption of antifungal, further 
endoscopies might be needed. Good glycemic 
control and rational antibiotic treatment will 
reduce the recurrent candida infection risk.13,25 
Pill-induced esophagitis is another type of 
esophagitis which is preventable by suggesting 
patients drink right after taking medicine.10
Manifestation on Gaster
Manifestation on gaster is the most frequent 
complication of diabetes mellitus in the 
gastrointestinal tract, which is gastroparesis. 
Gastroparesis is the retention of gastric contents or 
deceleration of gastric emptying without physical 
obstruction.28 Symptom from gastroparesis varies 
from early satiety, burping, heartburn, persistent 
nausea, paroxysmal vomiting, even decrease of 
body weight. However, these complaints can be 
overlapping with metabolic impairment, drugs 
adverse effect, or other diabetic complications.9 
Diabetic gastroparesis could affect the glycemic 
control leading to nutritional disorders and 
repeated hospitalization.
Gastroparesis is one complication with 
big effect to the glycemic control of diabetic 
patients.3 Deceleration of gastric emptying 
will affect patients undergoing treatment with 
an oral hypoglycemic agent or exogenous 
insulin. Slower gastric emptying will slow down 
absorption of the oral hypoglycemic agent, 
which lead to poor glycemic control. On the 
other hand, patients with exogenous insulin will 
encounter hypoglycemic episode from abruption 
of transportation in the gastrointestinal tract, 
so that absorption of consumed food is not 
enough to balance out administered insulin.3,29 
Mismatch in these two methods of treatment will 
result in long-term poor glycemic control, also 
recurrent exacerbation of worsening complaints, 
leading to nutritional disorders and repetitive 
hospitalizations.30
Diabetic gastroparesis usually appears in 
chronic diabetic patients with some risk factor 
such as other microangiopathy complications, 
neuropathy and nephropathy.3 Incidence of 
diabetic gastroparesis is higher in the female 
group, though the cause of such thing has not 
been found.21,31 Other risk factor is obesity, 
poor glycemic control, duration of diabetes 
for more than 10 years, also the existence of 
other complications.29,31,32 From anatomy and 
physiology, in diabetic gastroparesis, there is 
a change from the loss of the migration motor 
complex, dull gastric antrum contraction, and 
increasing of gastric pyloric spasm.28 Other 
changing factors are such as neural impairment 
containing nitrite oxide inhibitors, loss of ICC 
in gaster, fibrosis of gastric smooth muscle, 
and abnormal macrophage infiltration.15,33 
Neurohormonal factors such as glucagon-like 
peptide 1 and apolipoprotein E deficiency also 
prompt gastroparesis, so that drugs like GLP-
1 agonist needs to be reconsidered in diabetic 
gastroparesis patients.34
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Management
First, history approach including the 
symptoms of gastroparesis to its complications, 
duration of diabetes, and other cause of 
gastroparesis aside from diabetes.10 In physical 
examination, neuropathy, distended epigastrium, 
and succussion 1-hour postprandial might 
be found.32 Other metabolic tests to exclude 
including ketoacidosis, uremia, hypocalcemia, 
hypothyroid, complete blood test for infection 
or immunologic disorders, amylase test, and 
pregnancy test.13,29 Another further examination 
is upper gastrointestinal endoscopy to rule out 
gastric outlet obstruction. If obstruction was not 
found, gastroparesis can be confirmed by nuclear 
scintigraphy or endoscopy.
Endoscopy can suspect diabetic gastroparesis 
if food is found after 12-hours fasting.13 
Scintigraphy test is considered as the gold 
standard to diagnose gastroparesis by using 
Technetium TC-99M sulfur colloid which 
binds to food.35 This examination starts with the 
patient ingesting ingest low-fat egg-white meal 
and then undergoing scintigraphy measurement 
once every 4 hours. Diagnosis of gastroparesis 
is confirmed if there is gastric retention >10%. 
Based on American Neurogastroenterology and 
Motility, another way to perform the examination 
is by using 2 slices of bread and 2 eggs labeled 
with technetium and will be measured 1, 2, and 
4 hours postprandial by scintigraphy. Diagnosis 
can be established if retention is found >90% on 
the first hour, 60% on the second hour and >10% 
on the fourth hour.36 Other examinations such 
as pH measurement, temperature and pressure 
of gaster, breath test, and electrogastrogram are 
radiation free, unlike scintigraphy. However, 
they are less accepted by physicians as they are 
considered experimental and have problematic 
sensitivity and specificity.37,38
Management of diabetic gastroparesis 
starts from controlling blood glucose level 
and other exacerbating factors, followed by 
pharmacological therapy, or surgical therapy.10 
Maintaining glycemic control is the most 
important principle in treating gastroparesis 
by improving symptoms, as well as preventing 
recurrence of gastroparesis. Other exacerbating 
factors such as electrolyte imbalance and 
dehydration also need to be corrected.9 The next 
approach is diet modification, including avoiding 
things that can decelerate gastric emptying 
like alcohol, cigarettes, fatty food, and non-
digestible fibers such as vegetables and fruits.9 
Patients undergoing diet modification should 
be suggested to consume a low-fat diet in small 
portions more frequently. If this diet modification 
does not improve, then liquid based nutrition 
should be considered.39
If glycemic control and diet modification do 
not suffice, the help of pharmacological therapy 
is needed. Metoclopramide is a commonly used 
drug, which act centrally in the chemoreceptor 
trigger zone. Metoclopramide has been approved 
as a gastroparesis therapy and known to improve 
acute complaint for several weeks, but its long-
term effects are not clear yet, tardive dyskinesia 
and extrapyramidal syndrome are some of the 
noticeable adverse effects.40 Domperidone is 
still used in several countries. Working as type 
2 receptor antagonist, domperidone is also 
effective in an acute case with nausea, vomiting, 
and bloated feeling. One of its adverse effects is 
QTc interval elongation which can cause cardiac 
arrhythmia.41 Erythromycin, considered as one 
of the best drugs of choice, is reported to be the 
most effective drug to improve severe complaints 
if administrated intravenously with high dose 
followed orally for weeks. A well-known adverse 
effect for erythromycin is nausea and vomiting.42 
Cisapride, working as 5-HT4 agonist which 
accelerates gastric emptying and stimulates 
antrum contraction and improve antroduodenal 
coordination. Due to its adverse effect to 
heart, this drug has been withdrawn in several 
countries. But other 5-HT4 agonist groups has 
not been proven effective.43 Newest drug that 
can be used is ghrelin, a peptide produced by 
gastric fundal mucous and pancreas, working 
in gastric motility regulation. The use of ghrelin 
agonist, TZP 101, is still experimental but proven 
to improve symptoms in diabetic gastroparesis 
patients.44,45
If pharmacological therapy does not indicate 
results, then endoscopy therapy or surgical 
therapy might be needed. Endoscopic therapy 
is performed by injecting botulinum toxin to 
pylorus so that pylorus undergo paralysis and 
Alvin H. Kurniawan                                                                                                                     Acta Med Indones-Indones J Intern Med
268
improve the complaint of gastroparesis, though 
this method has not been proven significant.46 
Electric gastric stimulator implant has been 
used for more than 10 years and has shown 
to improve nausea and vomiting up to 80% 
patients, but some has been withdrawn due to 
the infection.47 Surgical approaches includes 
pyloroplasty, gastrectomy, or jejunostomy to 
improve complaints like nausea, vomiting, and 
bloating even though the results post-surgical 
is not clearly reported.48 However, endoscopic 
or surgical therapy still need to be followed 
with good glycemic control to maintain well-
functioning gastric emptying.
Manifestation on Intestines
The manifestation of diabetic complications 
on intestines are diarrhea, constipation, and 
fecal incontinence, especially during night 
time.49 Apart from upper gastrointestinal tract 
complaints, enteropathy could also be resulted 
by diseases other than diabetes such as celiac 
disease, lactose intolerance, drug reaction, and 
pancreas malfunction so that diabetic enteropathy 
complication needs a different approach and 
comprehensive management.20,50
The underlying pathophysiology of 
enteropathy complication is neuropathy and 
hyperglycemia. Constipation is the most 
common symptoms with 60% of long-term 
diabetic patients. Constipation is mainly occurred 
by the damaged myenteric nerve plexus, loss of 
ICC, and fibrosis of intestinal mucous leading to 
reduced motility of the intestines.10 Decelerated 
intestine motility cause stasis which leads to small 
intestine bacterial overgrowth (SIBO). SIBO will 
cause diarrhea on patients with diabetes mellitus 
and enteropathy complication. Diarrhea covers 
20% of diabetes mellitus patients.51 Diarrhea 
can also be generated by adverse effect of 
hypoglycemic agents such as metformin, alpha-
glucosidase inhibitor, glucagon-like peptide 
(GLP)-1 agonist, and dipeptidyl peptidase-4 
(DPP4) inhibitor.52,53 Enteropathy diarrhea on 
diabetes mellitus patients is often followed 
by fecal incontinence due to dysfunction of 
external and internal anal sphincter, and rectum 
contraction. This dysfunction is related to the 
hyperglycemic condition which has been proven 
to inhibit the function of anal sphincter and 
reduce the compliance of rectum by elevation of 
oxidative stress like nitrite oxide, therefore the 
fecal incontinence.54,55
Patients suffering under diabetic enteropathy 
particularly diarrhea and constipation should 
be ruled out of other possible causative 
agents notably induced hypoglycemic agents. 
Hypoglycemic agents should be stopped, dose 
readjusted, or replaced by other gastrointestinal 
tract friendlier agents.56 If enteropathy symptoms 
are still persistent, further examination including 
endoscopy, fecal culture, or lactose-free 
management should be considered to rule out 
lactose intolerance, or ceasing diarrhea inducing 
drugs.10 One of radiologic examination to 
understand enteropathy particularly constipation 
is by using radiopaque marker to measure 
the colon transit time.57 For diarrhea, jejunal 
aspiration is the gold standard to find out whether 
or not SIBO is exist, which can also be confirmed 
by breath test. However, these two examination 
has their limitation in sensitivity and specificity 
because of fully contaminated gastrointestinal 
tract.58 Manometry can be used for fecal 
incontinence, by which can confirm diagnosis 
by measuring decreased anal sphincter tone.20
Management
The most important thing in management 
of suspected diabetic enteropathy is to evaluate 
dehydration status and electrolyte imbalance 
because patient might need to be treated as 
inpatient. Just like in the gastroparesis, the initial 
approach is to reach good glycemic control 
and diet management, which is low-fat in a 
frequent small portion. If this approach fails, 
then additional pharmacological therapy is 
needed.20 For diarrhea, opioid group antidiarrheal 
drugs can be administered with caution of toxic 
megacolon and worsen bacterial overgrowth. 
For SIBO condition problem, selective antibiotic 
management will be needed. Rifaximin is the 
best agent based on researches for this disorder, 
selectively work in gastrointestinal tract, low 
resistance, and improve complaints for 33% 
to 99% of patients.59 For uncontrolled diabetic 
patients, somatostatin group such as octreotide 
and lanreotide has been reported to improve 
symptoms.58
Complaint of constipation can be managed 
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by sufficient hydration, high-fiber meals, and 
routine physical activities. On worse case 
scenario, osmotic laxative or lactulose will help. 
Constipation is often followed by abdominal 
pain. In this case, pain relief from antidepressant 
tricyclic or tetracyclic group can be given.29 Fecal 
incontinence often improve by itself within good 
glycemic control, but if the symptom persists, 
loperamide can be administered.60
PROGNOSIS
In spite of the various therapy on esophagus, 
gaster, and intestines, those therapies often 
hard to achieve and manifestations keep 
recurring. This is mainly due to poor glycemic 
control and aggravated by complications such 
as dehydration, electrolyte imbalance, and 
malnutrition, which intensify the morbidity of 
diabetes mellitus patients. Therefore, we need 
to improve the general condition of the patients 
and also maintain good glycemic control aside 
from resolving problems based on symptoms 
and manifestations and to prevent the recurring 
complications.
CONCLUSION
Diabetic gastroenteropathy is one of major 
morbidity and complication in diabetes mellitus 
patients, especially long-term patients or 
patients with neuropathy. Diagnosis of diabetic 
gastroenteropathy needs to be well observed and 
it is also important to rule out other possibilities. 
Management of the complications also needs 
a meticulous attention because aside from 
resolving those complaints, we also need to 
maintain good glycemic control. Furthermore, 
research for alternative therapies for diabetic 
gastroenteropathy, which are better in improving 
symptoms with fewer adverse effects, is highly 
recommended.
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